Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04803318 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Jan 1, 2025 to Jan 1, 2029
    • Study completion date: Jan 1, 2027 to Jan 1, 2037
    v4
  2. Primary completion date: Jan 1, 2023 to Jan 1, 2025
    • Study completion date: Jan 1, 2025 to Jan 1, 2027
    v3
  3. Phase: Not applicable to Phase 2v2 Show 9 more changesShow less
    • Enrollment target: 1 to 100
    • Primary completion date: Jan 1, 2022 to Jan 1, 2023
    • Primary endpoint revised
    • Study completion date: Jan 1, 2023 to Jan 1, 2025
    • Interventions: Treatment of Trametinib combined with Everolimus and Lenvatinib (Drug) to Combination of three inhibitors Trametinib, Everolimus and Lenvatinib (Drug)
    • Secondary endpoints expanded, about 7 words
    • Site contact updated
    • Eligibility criteria expanded, about 3 words
    • Study title shortened, about 3 words
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To study the clinical effect of Trametinib combined with Everolimus and Lenvatinib in the treatment of Recurrent/Refractory advanced solid tumors.
Trial Details
NCT Number NCT04803318
Lead Sponsor Second Affiliated Hospital of Guangzhou Medical University
Conditions
(from sponsor)		 Solid Tumor, Adult, Hepatocellular Carcinoma
Related terms Carcinoma, Hepatocellular
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov